Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of Topotecan [1]

Oncologist

Volumn 11, Issue 5, 2006, Pages 529-531

  Muggia, Franco ^a   Kosloff, Rebecca ^a   Liebes, Leonard ^a   Hochster, Howard ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MECHANISM; HUMAN; LETTER; LUNG CANCER; LUNG SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; TOPOTECAN;

EID: 33646886382     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-5-529     Document Type: Letter

References (15)

1. Armstrong DK, Spriggs D, Levin J et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The Oncologist 2005;10:686-694.
2. Markman M. Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. The Oncologist 2005;10:695-697.
3. Safra T, Moshe I, Levy T. Topotecan in ovarian cancer: schedules and doses, activity and toxicity. Cancer Invest 2006;24 (Suppl 1):1.
4. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-559.
5. Hochster H, Wadler S, Runowicz C et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999;17:2553-2561.
6. Hochster HS, Plimack ER, Mandeli J et al. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol 2006;100:324-329.
7. Mirchandani D, Hochster H, Leibes L et al. Prolonged oral topotecan (T): unacceptable gastrointestinal toxicity in two drug combinations. Proc Am Soc Clin Oncol 2001;2075a.
8. Mirchandani D, Hochster H, Hamilton A et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 2005;11:5912-5919.
9. Lu JM, Hochster H, Sorich J et al. Phase I study of oxaliplatin and topotecan infusion in patients with previously treated ovarian cancer. Proc Am Soc Clin Oncol 2003;22:463.
10. Houghton PJ, Cheshire PJ, Myers L et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-239.
11. Santana VM, Furman WL, Billups CA et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23:4039-4047.
12. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-4563.
13. Hudes G. Boosting bioavailability of topotecan: what do we gain? J Clin Oncol 2002;20:2918-2919.
14. Muggia FM. Boosting bioavailability to topotecan: what do we gain? Correspondence. J Clin Oncol 2003;21:177; author reply 177.
15. Rustin GJ, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054-4057.